Swiss registry tracking heart, kidney, liver and metabolic health
Records how often heart, kidney, liver and metabolic problems occur together in adults.
Plain-language title generated from the registry record
Registry title: Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- Medical Outpatient Department of the University Hospital BaselBasel, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT07084688
- Record updated
- 24 July 2025
- Original description
The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.Read full original descriptionShow less
Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry
The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.
Inclusion: At least 18 years of age; Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following:; For stage 0: Individuals without overweight/obesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD); Individuals with overweight/obesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD; Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD; Subclinical Atherosclerotic cardiovascular disease (ASCVD) or subclinical heart failure (HF) in individuals with excess/dysfunctional adiposity, other metabolic risk factors, or CKD in the clinical assessment[2]; Independent of CKM syndrome stages, individual with signs of hepatic steatosis on imaging; Willingness to provide informed consent.
Exclusion: Individuals with CKM syndrome stage 4 according to the AHA; Individuals with clinical cardiovascular disease including:; History of coronary artery disease, myocardial infarction, coronary artery intervention; History of atrial fibrillation; History of stroke; Symptomatic peripheral artery disease (>stage I); History of symptomatic HF; History of HF hospitalisation; Inability to sign informed consent.